Myelodysplastic Syndromes in Older Adults: Treatment Options and Support Strategies
Supported by the National Marrow Donor Program® (NMDP), Be The Match® and Aplastic Anemia and MDS International Foundation (AAMDSIF)
Release Date: June 25, 2018
Expiration Date: June 25, 2020
Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by ineffective hematopoiesis and cytopenias. MDS can be indolent or progress to bone marrow failure or AML. Allogeneic hematopoietic cell transplantation (HCT) is the only therapy for MDS with curative potential. Of the estimated 15,000 to 20,000 US patients diagnosed annually, >80% are >age 70 years. Care of patients with MDS requires understanding the disease in the context of an older population, and tailoring approaches to both disease risk and patient suitability for therapy.
In this free webinar a physician and nurse practitioner will present current research and case examples to illustrate treatment options and common experiences for older patients with MDS and their families. The goal of this activity is to ensure that members of a multidisciplinary team have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with MDS.
Hematology, oncology and BMT nurses; hematology, oncology and BMT social workers at intermediate to advanced levels of practice, experience and licensure; transplant center coordinators; payer case managers and other allied health professionals.
- Outline treatment considerations for older patients with myelodysplastic syndromes (MDS) based on comorbidities, disease risk level and patient risk stratification.
- Discuss evidence-based definitions of fitness to inform treatment decisions.
- Identify supportive care considerations for older adults undergoing treatment for MDS.
- Describe strategies for psychosocial support and education for older patients and their families.
Marlise R. Luskin, MD, MSCE
Dr. Luskin received her MD from the University of Pennsylvania Perelman School of Medicine in 2009. She completed residency training in Internal Medicine at Brigham and Women's Hospital, followed by a fellowship in Hematology and Oncology at the University of Pennsylvania. She joined Dana-Farber as a member of the Adult Leukemia program in 2016. Her research focuses on outcomes research in hematologic malignancies as well as the development of novel therapies for patients with acute leukemia and MDS. She has a particular interest studying the impact of acute leukemia and MDS in older patients.
Ilene Galinsky, NP
Ilene Galinsky is the Senior Program Research Nurse Practitioner for the Adult Leukemia Program with the Dana Farber Cancer Institute (DFCI) and Brigham and Women’s Hospital /BWH in Boston, Massachusetts.
Ilene has worked at the DFCI for 29 years in various positions, first as a selected nurse intern on the oncology inpatient service; advancing to Charge Nurse; and then Program Nurse in Harvard’s Joint Center for Radiation Therapy. Ilene first joined the DFCI/BWH Leukemia Program as a program/research RN. After receiving a Master’s Degree in Adult Primary Care in 2004, she became the Senior Program Research Nurse Practitioner where she oversees many aspects of clinical research activities while providing direct care for many patients with leukemia and related disorders.
Where she has implemented a collaboration meeting with pharmacy and nursing at both the inpatient and outpatient setting. In addition, she was recently instrumental in assisting in the establishment of the strategic team for CAR T cells.
She serves as the co-chair of the Alliance (national oncology trial cooperative group) Oncology Nurse Committee, as well as nurse liaison to the Leukemia, Myeloma, and Transplant Alliance Committees. She is a member of American Society of Hematology and Oncology Nursing Society. She is also a member of the oncology board of the ABIM, serving as the non MD representative.
Participants must complete and submit the evaluation for the activity in order to receive a certificate of participation.
Certificates will be issued via email.
If you have any questions regarding this activity or for assistance for people with disabilities, grievances, please email firstname.lastname@example.org.